EXJADE Drug Patent Profile

Which patents cover Exjade, and what generic alternatives are available?

Exjade is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EXJADE is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exjade

A generic version of EXJADE was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for EXJADE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	36
Drug Prices:	Drug price information for EXJADE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXJADE
What excipients (inactive ingredients) are in EXJADE?	EXJADE excipients list
DailyMed Link:	EXJADE at DailyMed

See drug prices for EXJADE

Recent Clinical Trials for EXJADE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 2
DisperSol Technologies, LLC	Phase 2
Fondazione Italiana Sindromi Mielodisplastiche-ETS	Phase 2

See all EXJADE clinical trials

Pharmacology for EXJADE

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Paragraph IV (Patent) Challenges for EXJADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXJADE	Tablets for Suspension	deferasirox	125 mg, 250 mg, and 500 mg	021882	1	2011-10-28

US Patents and Regulatory Information for EXJADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005	AB	RX	Yes	No
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005	AB	RX	Yes	No
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-003	Nov 2, 2005	AB	RX	Yes	Yes

Expired US Patents for EXJADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-003	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005

EU/EMA Drug Approvals for EXJADE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for EXJADE

See the table below for patents covering EXJADE around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	333308	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Denmark	0914118
Poland	330119

Supplementary Protection Certificates for EXJADE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	SPC/GB07/002	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
0914118	300248	Netherlands		300248, 20170624, EXPIRES: 20210827
0914118	290	Finland

Market Dynamics and Financial Trajectory for EXJADE (Deferasirox)

Last updated: December 28, 2025

Executive Summary

EXJADE (Deferasirox), a pioneering oral iron chelator developed by Novartis, has significantly impacted iron overload management since its approval. This report delves into the current market landscape, analyzing key drivers, competitive positioning, regulatory environment, and projected financial performance. Over the past decade, the drug's revenue trajectory has been shaped by expanding indications, increased adoption in thalassemia and myelodysplastic syndromes (MDS), and evolving pricing strategies. With an increasing global burden of iron overload conditions, particularly in emerging markets, EXJADE's market prospects remain robust. However, competition from alternative chelators and biosimilars, alongside regulatory challenges, influence future growth.

1. Overview of EXJADE (Deferasirox)

Attribute	Details
Approved Indications	Iron overload management in thalassemia, MDS
Mechanism of Action	Oral iron chelation by binding excess iron
Formulation	Tablets, dispersible tablets
Approval Date	2005 (FDA), 2006 (EMA)
Manufacturer	Novartis

2. Market Size and Segmentation

Global Market Valuation (2022-2025)

Year	Estimated Market Size (USD billion)	Compound Annual Growth Rate (CAGR)
2022	$1.14 billion	—
2023	$1.26 billion	10.5%
2024	$1.40 billion	11.1%
2025	$1.55 billion	10.7%

Sources: Allied Market Research [1], Grand View Research [2]

Regional Market Distribution (2022)

Region	Market Share	Key Markets
North America	39%	US, Canada
Europe	26%	Germany, France, UK
Asia-Pacific	25%	China, India, Japan
Rest of World	10%	Latin America, Middle East

Patient Population

Condition	Estimated Patients (Global)	Key Factors Influencing Numbers
Thalassemia Major	80,000	High prevalence in the Mediterranean, South Asia
Myelodysplastic Syndromes	85,000	Increasing incidence with aging populations
Other Iron Overload Conditions	50,000	Post-transplant, sickle cell disease

3. Market Drivers

Increasing Burden of Iron Overload Disorders

• The rise in hereditary blood disorders (e.g., thalassemia, sickle cell) and side effects of chronic transfusions propel demand for chelation therapy.
• The aging population and rising MDS cases contribute to expanding patient pools.

Efficacy and Safety Profile of EXJADE

• Demonstrates superior compliance due to oral dosing compared to injectable alternatives like deferoxamine.
• Acceptable safety profile with manageable adverse events (GI disturbances, renal or hepatic effects).

Regulatory Approvals and Expanding Indications

• Approved for pediatric and adult populations.
• Expanded approval includes secondary iron overload in non-transfusion-dependent conditions.

Pricing Strategies and Reimbursement Policies

• Tiered pricing and reimbursement support adoption across diverse healthcare systems.
• Novartis invested in direct-to-patient education and hospital-based delivery models.

Emerging Markets

• Rapid growth in Asia-Pacific driven by increased screening and healthcare investments.
• Government initiatives aimed at an improved blood safety and chronic disease management.

4. Competitive Landscape

Competitors	Market Share (2022)	Key Attributes
Exjade (Novartis)	~65%	Established first oral chelator, broad approval
Ferriprox (Ferprelserox)	~15%	Approved for certain patient subsets, more side effects
Deferoxamine (Injectable)	~10%	Older, less preferred due to administration method
Chelation biosimilars/Generics	~10%	Emerging, pricing-driven entrant

Market Position of EXJADE

• Leading oral chelator with a strong global brand presence.
• Revenue driven by key indications like thalassemia and MDS.
• Faces competition from newer molecules and biosimilars; yet, maintains dominance via established safety profile and market inertia.

5. Financial Trajectory and Revenue Forecasts

Year	Estimated Revenue (USD billion)	CAGR (2019-2025)	Key Factors Influencing Revenue
2019	$1.22 billion	—	Steady adoption, expanding indications
2020	$1.28 billion	4.9%	COVID-19 impact, slower growth
2021	$1.33 billion	3.9%	Recovery in elective procedures
2022	$1.41 billion	6.0%	Accelerated growth in emerging markets
2023	$1.55 billion	10.0% projected	Increased approvals, new formularies

Assumptions: Continued expansion into emerging markets, demographic shifts, and competitive landscape stabilization.

Top Revenue Contributors by Region (2022)

Region	Revenue Share	Key Contributors
North America	39%	US-driven sales, insurance reimbursement
Europe	26%	Established healthcare infrastructure
Asia-Pacific	25%	Rapid patient base growth, increasing healthcare access
Rest of the World	10%	Market entry phase, low penetration

6. Regulatory and Policy Environment

• FDA and EMA approvals underpin global adoption.
• Pricing and reimbursement policies vary by country, influencing revenue potential.
• Off-label use restrictions affect prescribing behaviors, especially in emerging indications.
• Post-marketing surveillance emphasizing safety profiles influence ongoing approvals.

7. Comparative Analysis of Key Oral Chelators

Parameter	EXJADE (Deferasirox)	Ferriprox (Deferiprone)	Deferoxamine (Injectable)
Oral Administration	Yes	Yes	No
Approval Year	2005 (FDA)	2011	1960s
Efficacy	High, with compliance	Moderate, used in specific cases	Effective but less preferred
Side Effect Profile	Manageable	Significant concern (neutropenia)	Side effects less tolerated

8. Challenges and Risks to Future Growth

Challenge	Details
Competition from biosimilars	Potential price erosion and market share loss
Safety concerns	Renal and hepatic adverse events may restrict use
Regulatory hurdles	Delays in approvals or label updates
Market saturation	Limited untapped patient populations in developed markets

9. Future Outlook and Opportunities

Opportunity	Strategic Focus
Expansion into non-transfusion iron overload	Broaden indications, especially in MDS and secondary conditions
Personalized medicine approaches	Biomarker-driven treatments to optimize dosing and safety
New formulations and delivery	Improving adherence through novel delivery methods
Emerging markets	Tailored pricing and distribution, leveraging local health policies

Key Takeaways

• Market growth is driven by increasing global burden of iron overload disorders, with a projected CAGR exceeding 10% through 2025.
• EXJADE maintains leadership due to its efficacy, oral dosing, and broad approvals, though faces competitive pressure.
• Emerging markets offer significant upside, with regulatory and reimbursement frameworks evolving favorably.
• Biosimilar and generic competition will likely influence pricing strategies, necessitating innovation in formulations and indications.
• Investments in personalized medicine and expanded indications represent future growth avenues.

FAQs

1. What are the key factors driving the adoption of EXJADE globally?

The combination of proven efficacy, oral administration advantage, expanding indications, and supportive regulatory approvals drive adoption. Increased prevalence of transfusion-dependent diseases in emerging markets also accelerates uptake.

2. How does EXJADE compare to its main competitors in terms of efficacy and safety?

EXJADE offers comparable efficacy to deferoxamine with better compliance due to oral dosing. Its safety profile is generally acceptable, though renal and hepatic monitoring is necessary. Competing agents like deferiprone have different side effect profiles, which can influence choice depending on patient factors.

3. What regulatory challenges could impact EXJADE’s growth future?

Regulatory authorities may impose safety restrictions or require further post-marketing data, especially concerning renal and hepatic adverse events. Delays in approvals for new indications or markets could impede growth.

4. Which regions represent the most significant growth opportunities for EXJADE?

Asia-Pacific and Latin America are pivotal, given demographic trends and rising healthcare investments. Regulatory environments supportive of expanding indications further enhance prospects.

5. How might biosimilar development influence the competitive landscape?

Biosimilars could offer lower-cost alternatives, pressuring Novartis to optimize pricing. Differentiation through extended indications, formulations, and personalized therapy will be critical.

---

References

1. Allied Market Research. "Global Iron Chelation Therapy Market." 2022.
2. Grand View Research. "Iron Chelators Market Size & Industry Analysis." 2022.
3. Novartis Pharmaceuticals. "EXJADE (Deferasirox) Product Label." 2023.
4. FDA & EMA approval documents. 2005-2022.
5. World Health Organization. "Sickle Cell Disease and Thalassemia Prevalence." 2021.

---

Disclaimer: This analysis synthesizes publicly available data and industry insights as of early 2023. Actual market conditions may evolve, and specific financial forecasts are subject to change based on regulatory and competitive developments.